Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly

Abstract

Objective: Asprosin (ASP) is a modern adipokine produced from white adipose tissue that is linked to metabolic disorders such as obesity and diabetes. Acromegalic syndrome results from excessive pituitary growth hormone (GH) secretion, leading to increased insulin-like growth factor-1 (IGF-1) production, usually due to a pituitary adenoma. The serum ASP levels were higher in acromegaly patients (AC-PTs) than in healthy controls. The aim of the study was to explore ASP levels in AC-PTs compared with healthy controls, considering gender, diabetes status, treatment duration, and hypertension. Materials and Methods: Fifty AC-PTs with different body mass index, sex, age, diabetes, and blood pressure were enrolled in this study. IGF-1, GH, and fasting blood glucose (FBG) levels were measured alongside 30 healthy controls. In addition, enzyme-linked immunoassay (ELISA) was used to measure ASP. Results: There was no significant difference in ASP levels between AC-PTs and healthy controls (p>0.05). Moreover, the current study showed no statistically significant difference in ASP levels among the subgroups categorized according to the patient’s gender, diabetes status, hypertension, and treatment course. Conclusion: ASP levels revealed no difference between Iraqi AC-PTs and control group; ASP is not affected by hormonal changes that are typically associated with acromegaly.

Keywords

• Acromegaly
• Adipokine
• Asprosin
• GH
• IGF-1
• Pituitary Adenoma

References

1. 1. Vilar L, Vilar ÇF, LYra R, LYra R, Naves LA. AcromegalY: clinical features at diagnosis. PituitarY 2017; 20: 22-32. google scholar
2. 2. Çolao A, Pivonello Ç, Grasso LFS, Pirchio R. AcromegalY. ln: La Rosa, S., Uccella, S. (eds) Endocrine PathologY. EncYclopedia of PathologY. Çham: Springer; 2022. p. 9-11. google scholar
3. 3. Ershadinia N, Tritos NA. Diagnosis and treatment of acromegalY: an update. MaYo Çlin Proc 2022; 97(2): 333-46. google scholar
4. 4. Saadi MT, Mohammed NUG, Abed BA, Farhan LO, Salman lN. ValiditY of galactin-3 in acromegalY: comparison with traditional markers. lr J Med Sci 2024; 193(4): 1837-41. google scholar
5. 5. Farhan LO, Abed BA, Salman lN. lnsulin like growth factor binding protein 7 as a novel diagnostic marker in sera of lraqi patients with acromegalY. Baghdad Sci J 2023; 20(3 Suppl): 0979. google scholar
6. 6. Çhanson P, Salenave S. AcromegalY. Orphanet J Rare Dis 2008; 3: 1-17. google scholar
7. 7. Ghannawi L, Gharab K, Hadi M, Shakir O, Rahmah A. Spexin level in growth hormone deficiencY lraqi children. Ukr Biochem J 2024; 96(4): 55-61. google scholar
8. 8. Turki TG. The Association of growth hormone releasing hormone gene polYmorphism with acromegalY in patients from lraq. AL-Qasim Green UniversitY, Master thesis. 2023. google scholar

9. 9. Sharma R, Kopchick JJ, Puri V, Sharma VM. Effect of growth hormone on insulin signaling. Mol Çell Endocrinol 2020; 518: 111038. google scholar
10. 10. Olarescu NÇ, Bollerslev J. The impact of adipose tissue on insulin resistance in acromegalY. Trends Endocrinol Metab 2016; 27(4): 226-37. google scholar
11. 11. Kuker AP, Shen W, Jin Z, Çhen J, Bruce JN, Freda PU. Long-term outcome of bodY composition, ectopic lipid, and insulin resistance changes with surgical treatment of acromegalY. J Endocr Soc 2023; 7(5): bvad028. google scholar
12. 12. Abreu A, Român-Gonzâlez A, Tovar H, Maestre K, Builes-Barrera CA, Nessim E, et al. Characterizing the burden of uncontrolled acromegalY-a description of real-world patient characteristics in Colombia. Rev Colomb Endocrinol Diabetes Metab 2022; 9(2): e678. google scholar
13. 13. Bona C, Prencipe N, Berton A, Bioletto F, Parasiliti-Caprino M, Gasco V, et al. Mean GH profile is more accurate than single fasting GH in the evaluation of acromegalY disease control during somatostatin receptor ligands therapY. J Endocrinol lnvest 2022; 45(10): 1955-65. google scholar
14. 14. Peixe C, Sânchez-Garcîa M, Grossman AB, Korbonits M, Marques P. Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or lGF-1 levels do not alwaYs diagnose acromegalY. Growth Horm lGF Res 2022; 64: 101467. google scholar
15. 15. Gozel N, Kilinc F. lnvestigation of plasma asprosin and saliva levels in newlY diagnosed tYpe 2 diabetes mellitus patients treated with metformin. EndokrYnol Pol 2021; 72(1): 37-43. google scholar
16. 16. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell 2016; 165(3): 566-79. google scholar
17. 17. BaYkus Y, Yavuzkir S, UstebaY S, Ugur K, Deniz R, AYdin S. Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus. Peptides 2019; 120: 170132. google scholar
18. 18. Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan l, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polYcYstic ovarY sYndrome. GYnecol Endocrinol 2019; 35(3): 220-3. google scholar
19. 19. Atta SE, Abed BA, Salman lN, Ghannawi LA. Review of Asprosin as new biomarker for diagnosis of different diseases. Univ Thi-Qar J Sci 2023; 10(2): 160-4. google scholar
20. 20. Janoschek R, Hoffmann T, Morcos YAT, Sengle G, Dötsch J, Hucklenbruch-Rother E. Asprosin in pregnancY and childhood. Mol Cell Pediatr 2020; 7: 1-5. google scholar
21. 21. Farhan LO, Salman lN. A review on the role of novel adipokine lsthmin-1 and Subfatin in human tYpe 2 diabetes mellitus. Univ Thi-Qar J Sci 2023; 10(2): 181-6. google scholar
22. 22. Lefta NA, Abed AY, Abed BA. Estimation of Asprosin levels in female lraqi patients with tYpe 2 diabetes and hYpothYroidism. J Med Chem Sci 2023; 6(2): 433-9. google scholar
23. 23. Liu Y, Long A, Chen L, Jia L, Wang Y. The Asprosin-OLFR734 modüle regulates appetitive behaviors. Cell Discov 2020; 6(1): 19. google scholar
24. 24. Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel plaYer in metabolic diseases. Front Endocrinol 2020; 11: 64. google scholar
25. 25. Wang CY, Lin TA, Liu KH, Liao CH, Liu YY, Wu VC, et al. Serum asprosin levels and bariatric surgerY outcomes in obese adults. lnt J Obes (Lond) 2019; 43(5): 1019-25. google scholar
26. 26. Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y, et al. OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell Metab 2019; 30(2): 319-28.e8. google scholar
27. 27. Nijenhuis-Noort EC, Berk KA, Neggers SJ, van der LelY AJ. The fascinating interplaY between growth hormone, insulin-like growth factor-1, and insulin. Endocrinol Metab 2024; 39(1): 83. google scholar
28. 28. Wiecek M, SzYmura J, KusmierczYk J, Lipowska M, SzYgula Z. Whole-bodY crYotherapY improves asprosin secretion and insulin sensitivitY in postmenopausal women-perspectives in the Management of tYpe 2 diabetes. Biomolecules 2023; 13(11): 1602. google scholar
29. 29. Muthu ML, Reinhardt DP. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. J Cell Commun Signal 2020; 14(2): 159-73. google scholar
30. 30. Kim JH, Chae HW, Chin SO, Ku CR, Park KH, Lim DJ, et al. Diagnosis and treatment of growth hormone deficiencY: a position statement from the Korean Endocrine SocietY and Korean SocietY of Pediatric EndocrinologY. Endocrinol Metab 2020; 35(2): 272. google scholar
31. 31. Hekim MG, Kelestemur MM, Bulmus FG, Bilgin B, Bulut F, Gokdere E, et al. Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. Arch PhYsiol Biochem 2023; 129(5): 1038-44. google scholar
32. 32. Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in tYpe 2 diabetes mellitus and independentlY associated with fasting glucose and triglYceride. Clin Chim Acta 2019; 489: 183-8. google scholar
33. 33. Wang M, Yin C, Wang L, Liu Y, Li H, Li M, et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesitY. Ann Nutr Metab 2020; 75(4): 205-12. google scholar
34. 34. Sunnetci Silistre E, Hatipogl HU. lncreased serum circulating asprosin levels in children with obesitY. Pediatr lnt 2020; 62(4): 467-76. google scholar
35. 35. Moradi N, Fouani FZ, Vatannejad A, Bakhti Arani A, Shahrzad S, Fadaei R. Serum levels of asprosin in patients diagnosed with coronarY arterY disease (CAD): a case-control studY. Lipids Health Dis 2021; 20(1): 88. google scholar
36. 36. Ke X, Duan L, Gong F, Zhang Y, Deng K, Yao Y, et al. Serum levels of asprosin, a novel adipokine, are significantlY lowered in patients with acromegalY. lnt J Endocrinol 2020: 8855996. google scholar
37. 37. Kumar U, Singh S. Role of somatostatin in the regulation of central and peripheral factors of satiety and obesity. Int J Mol Sci 2020; 21(7): 2568. google scholar
38. 38. Hoffmann JG, Xie W, Chopra AR. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes 2020; 69(4): 559-66. google scholar
39. 39. Wojciak G, Szymura J, Szygula Z, Gradek J, Wiecek M. The effect of repeated whole-body cryotherapy on SIRT1 and SIRT3 concentrations and oxidative status in older and young men performing different levels of physical activity. Antioxidants 2020; 10(1): 37. google scholar
40. 40. Liu L, Liu Y, Huang M, Zhang M, Zhu C, Chen X, et al. The effects of asprosin on exercise-intervention in metabolic diseases. Front Physiol 2022; 13: 907358. google scholar
41. 41. Challa TD. Regulation of adipogenesis and energy metabolism through the cross-talk between adipose tissue, gastrointestinal wall and the brain: Evidence from adipokines and incretin hormones. ETH Zurich, Doctoral thesis; 2014. google scholar
42. 42. Dal J, Skov BG, Andersen M, Feldt-Rasmussen U, Feltoft CL, Karmisholt J, et al. Sex differences in acromegaly at diagnosis: a nationwide cohort study and meta-analysis of the literature. Clin Endocrinol 2021; 94(4): 625-35. google scholar
43. 43. Wang W, Duan X, Huang Z, Pan Q, Chen C, Guo L. The GH-IGF-1 axis in circadian rhythm. Front Mol Neurosci 2021; 14: 742294. google scholar